Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised Dose-Optimisation Study to Evaluate the Efficacy and Safety of Cobitolimod in Moderate to Severe Active Ulcerative Colitis Patients

NCT03178669 is registered in ClinicalTrials.gov with InDex Pharmaceuticals as lead sponsor.

NCT NCT03178669
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03178669 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised Dose-Optimisation Study to Evaluate the Efficacy and Safety of Cobitolimod in Moderate to Severe Active Ulcerative Colitis Patients
Lead sponsor
InDex Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
June 21, 2017
Completion date
August 30, 2019
Enrollment
213 (actual)
Sites
64

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis